ALTUVIIIO™ approved by the U.S. FDA: this positive event triggers impairment reversal, positively impacting 2022 IFRS net income; no change on business net income (non-IFRS)

https://ift.tt/U2aApDw

from Sanofi - Aventis Groupe https://ift.tt/5SB91vO
via IFTTT